Milestone Scientific Expands Adoption of CompuFlo® Epidural System with Commercial Rollout at Pain Doctors Medical LLC
Milestone Scientific (NYSE: MLSS) announced the commercial implementation of its CompuFlo® Epidural System at Pain Doctors Medical , following a successful evaluation by Dr. Ilana Etelzon. The system, which employs proprietary Dynamic Pressure Sensing Technology®, provides real-time verification of epidural needle placement to enhance patient safety and procedural efficiency.
The implementation follows the recent Medicare price assignment for the CompuFlo® system, which is helping drive broader accessibility across interventional pain management centers. The technology offers real-time feedback for needle placement confirmation, improving procedural accuracy and safety in pain management procedures.
Milestone Scientific (NYSE: MLSS) ha annunciato l'implementazione commerciale del suo CompuFlo® Epidural System presso Pain Doctors Medical, a seguito di una valutazione positiva da parte della dott.ssa Ilana Etelzon. Il sistema, che utilizza la Dynamic Pressure Sensing Technology® proprietaria, fornisce una verifica in tempo reale del posizionamento dell'ago epidurale per migliorare la sicurezza dei pazienti e l'efficienza procedurale.
L'implementazione segue l'assegnazione recente del prezzo Medicare per il sistema CompuFlo®, che sta contribuendo a garantire una maggiore accessibilità nei centri di gestione del dolore interventistico. La tecnologia offre un feedback in tempo reale per la conferma del posizionamento dell'ago, migliorando l'accuratezza e la sicurezza delle procedure di gestione del dolore.
Milestone Scientific (NYSE: MLSS) anunció la implementación comercial de su CompuFlo® Epidural System en Pain Doctors Medical, tras una evaluación exitosa por parte de la Dra. Ilana Etelzon. El sistema, que utiliza la Dynamic Pressure Sensing Technology® patentada, proporciona verificación en tiempo real del posicionamiento de la aguja epidural para mejorar la seguridad del paciente y la eficiencia del procedimiento.
La implementación sigue a la reciente asignación de precios de Medicare para el sistema CompuFlo®, lo que está ayudando a impulsar una mayor accesibilidad en los centros de manejo del dolor intervencionista. La tecnología ofrece retroalimentación en tiempo real para la confirmación del posicionamiento de la aguja, mejorando la precisión y seguridad en los procedimientos de manejo del dolor.
Milestone Scientific (NYSE: MLSS)는 CompuFlo® Epidural System의 상업적 구현을 Pain Doctors Medical에서 발표했으며, 이는 Ilana Etelzon 박사에 의한 성공적인 평가를 기반으로 합니다. 이 시스템은 독점적인 Dynamic Pressure Sensing Technology®를 사용하여 환자 안전과 절차 효율성을 높이기 위해 경막외 바늘 배치의 실시간 확인을 제공합니다.
이번 구현은 CompuFlo® 시스템에 대한 최근 Medicare 가격 책정 후에 이루어졌으며, 이는 개입적 통증 관리 센터의 접근성을 확대하는 데 기여하고 있습니다. 이 기술은 바늘 배치 확인을 위한 실시간 피드백을 제공하여 통증 관리 절차에서의 정확성과 안전성을 향상시킵니다.
Milestone Scientific (NYSE: MLSS) a annoncé la mise en œuvre commerciale de son CompuFlo® Epidural System chez Pain Doctors Medical, après une évaluation réussie par le Dr Ilana Etelzon. Le système, qui utilise la Dynamic Pressure Sensing Technology® propriétaire, fournit une vérification en temps réel du placement de l'aiguille épidurale pour améliorer la sécurité des patients et l'efficacité des procédures.
Cette mise en œuvre fait suite à l'attribution récente des prix Medicare pour le système CompuFlo®, ce qui contribue à favoriser une plus grande accessibilité dans les centres de gestion de la douleur interventionnelle. La technologie offre un retour d'information en temps réel pour la confirmation du placement de l'aiguille, améliorant l'exactitude et la sécurité des procédures de gestion de la douleur.
Milestone Scientific (NYSE: MLSS) gab die kommerzielle Implementierung seines CompuFlo® Epidural Systems bei Pain Doctors Medical bekannt, nachdem Dr. Ilana Etelzon eine erfolgreiche Bewertung durchgeführt hatte. Das System, das die proprietäre Dynamic Pressure Sensing Technology® verwendet, bietet eine Echtzeitverifizierung der Platzierung der Epiduralnadel, um die Sicherheit der Patienten und die Effizienz des Verfahrens zu verbessern.
Die Implementierung folgt der kürzlichen Preiszuweisung durch Medicare für das CompuFlo®-System, was dazu beiträgt, die Zugänglichkeit in intervenierenden Schmerzmanagementzentren zu erhöhen. Die Technologie bietet Echtzeit-Feedback zur Bestätigung der Nadelplatzierung und verbessert die Genauigkeit und Sicherheit in Schmerzmanagementverfahren.
- Commercial implementation of CompuFlo® Epidural System at a new medical center
- Recent Medicare price assignment supporting broader market accessibility
- Clinical validation and adoption by board-certified pain management expert
- None.
Insights
The commercial rollout of CompuFlo® at Pain Doctors Medical marks a strategic milestone in MLSS's market penetration strategy, particularly following the important Medicare price assignment. This implementation carries several key implications for investors:
The pain management market presents a substantial opportunity, with over 7 million epidural procedures performed annually in the U.S. alone. The CompuFlo® system's ability to provide real-time verification addresses a critical patient safety concern, as traditional epidural procedures have a failure rate of up to 30% using conventional methods.
The Medicare coverage is particularly significant as it: 1) Reduces financial barriers to adoption 2) Provides validation of the technology's clinical utility 3) May influence private insurers to follow suit. This combination of factors could accelerate market penetration, especially among the nation's 7,000+ pain management centers.
While this single implementation may not immediately impact revenues significantly, it represents a valuable reference site and validation from a board-certified expert. The positive testimonial from Dr. Etelzon could serve as a powerful tool for driving adoption among other pain management specialists, potentially creating a network effect in this specialized medical community.
Dr. Ilana Etelzon Integrates CompuFlo® Epidural System into Practice Following Positive Clinical Experience
ROSELAND, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the commercial implementation of its CompuFlo® Epidural System at Pain Doctors Medical LLC, a specialized interventional pain management center. This rollout follows a successful evaluation led by Dr. Ilana Etelzon, MD, a board-certified expert in Interventional Pain Management and Physical Medicine & Rehabilitation Medicine, who has integrated the technology into her practice to enhance patient safety and procedural efficiency.
The CompuFlo® Epidural System uses Milestone Scientific’s proprietary Dynamic Pressure Sensing Technology® to provide real-time verification of epidural needle placement. This precision-driven approach improves safety and reduces the risk of complications, allowing for greater confidence in pain management procedures.
Dr. Etelzon commented, “The CompuFlo® Epidural System represents a significant advancement in epidural administration. The ability to confirm needle placement with real-time feedback not only enhances procedural accuracy but also provides peace of mind for both physicians and patients. Integrating this technology into my practice at Pain Doctors Medical LLC allows us to deliver safer and more effective pain management solutions.”
This launch follows the recent Medicare price assignment for the CompuFlo® Epidural System, which is helping drive broader accessibility across interventional pain management and rehabilitation centers. With a strong track record of clinical validation, the system is increasingly being recognized as an essential tool for improving patient care.
Neal Goldman, Chairman and Interim Chief Executive Officer of Milestone Scientific, added, “Expanding our reach within interventional pain management centers like Pain Doctors Medical LLC is a crucial step in broadening the reach of our CompuFlo® technology. Dr. Etelzon’s positive experience with the system reaffirms its clinical benefits, and we are committed to furthering its adoption across leading pain management providers. As reimbursement coverage continues to strengthen, we anticipate accelerating growth within this sector.”
About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS), a technology focused medical research and development company that patents, designs and develops innovative injection technologies and instruments for medical and dental applications. Milestone Scientific’s computer-controlled systems are designed to make injections precise, efficient and increase the overall patient comfort and safety. Their proprietary DPS Dynamic Pressure Sensing Technology® instruments is the platform to advance the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions of subcutaneous drug delivery, including local anesthetic. To learn more, view the MLSS brand video or visit milestonescientific.com.
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2023. The forward-looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
Contact:
Crescendo Communications, LLC
Email: mlss@crescendo-ir.com
Tel: 212-671-1020
FAQ
What is the recent commercial expansion announced by Milestone Scientific (MLSS)?
How does the CompuFlo® Epidural System enhance patient safety?
What recent reimbursement development supports MLSS's market expansion?
What technology does MLSS's CompuFlo® Epidural System use?
